Results 201 to 210 of about 98,175 (244)

Efficient Enantiomeric Selectivity Separation Via Homochiral Graphene Oxide Membrane

open access: yesENERGY &ENVIRONMENTAL MATERIALS, EarlyView.
A new type of chiral graphene oxide (GO) membrane is proposed that exhibits a separation factor of up to 20.1 as well as a preferential enantiomer flux of 4.5 mmol m−2 h−1. Moreover, the only first FPLC‐compatible column has been further developed via stacking these chiral GO membranes.
Junbo Wang   +10 more
wiley   +1 more source

Thermochromic Radiative Cooling Coatings with Robust Superhydrophobicity for Energy‐Efficient Buildings

open access: yesENERGY &ENVIRONMENTAL MATERIALS, EarlyView.
A scalable, color‐adaptive radiative cooling coating is developed to enable dynamic spectral regulation via a reversible thermochromic transition at ~45 °C and a high solar reflectance of 91.7%. The coating achieves 4.44 °C outdoor sub‐ambient cooling while providing robust superhydrophobicity and environmental durability through its micro/nano ...
Ziqi Li   +8 more
wiley   +1 more source

Data on the natural ventilation performance of windcatcher with anti-short-circuit device (ASCD). [PDF]

open access: yesData Brief, 2016
Nejat P   +4 more
europepmc   +1 more source

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu   +3 more
wiley   +1 more source

Impacts of boundary walls on natural ventilation behavior in low-cost single-story residential buildings

open access: green, 2023
Costa, Isabely Penina Cavalcanti da, 1989-   +2 more
openalex   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy